Voluntary announcement - ascletis' asc36_35fdc demonstrated potential for once-monthly to once-quarterly dosing and robust weight-loss in preclinical studies presented at easd 2026
Filed with HKEX · Stock code 1672 ·
6ix hasn’t read this filing yet.
View original source (HKEXnews)Company analysis
Earlier from Ascletis Pharma
- Interim Report 2026
- Ascletis Announces Positive Results from 28-Day Proof-of-Concept Clinical Study in U.S. for ASC50, a First-in-Class and Best-in-Class Oral Small Molecule IL-17A Inhibitor for the Treatment of Plaque Psoriasis
- Ascletis Announces Initiation of Phase I Study in U.S. for Oral Amylin Receptor Peptide Agonist ASC36 for the Treatment of Obesity
- Ascletis Announces Inclusion in the Hong Kong Stock Connect List under the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect Programs